A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin's lymphoma

Clin Lymphoma. 2005 Jun;6(1):56-60. doi: 10.3816/clm.2005.n.030.

Authors

Michael Crump¹, Lois Shepherd, Boris Lin

Affiliation

¹ Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, and National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada. michael.crump@uhn.on.ca

PMID: 15989710
DOI: 10.3816/clm.2005.n.030

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase III
Comparative Study
Randomized Controlled Trial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / administration & dosage
Clinical Trials as Topic
Cytarabine / administration & dosage
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Dexamethasone / administration & dosage
Gemcitabine
Humans
Lymphoma, B-Cell / drug therapy*
Lymphoma, B-Cell / pathology
Lymphoma, T-Cell / drug therapy*
Lymphoma, T-Cell / pathology
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Cytarabine
Deoxycytidine
Rituximab
Dexamethasone
Cisplatin
Gemcitabine